HANSHOW
Deploying scalable and affordable enterprise grade IoT applications in the retail industry has previously been restricted by technology limitations. But digital retail solutions leader Hanshow has now developed a SaaS solution that accelerates this digital transformation by connecting store shelves to retailers, store operators, and customers on an unprecedented scale by managing more than 10 million IoT devices across a vast network of Ahold Delhaize stores in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210607005244/en/
Ahold Delhaize and Hanshow began partnering in 2018 to install electronic shelf labels (ESL) and other digital solutions at select stores in Europe. This later expanded to cover hundreds of stores across Europe and over 10 million ESL – a tremendous number of devices to sync and manage.
ESLs are the building blocks of retail digitization, and effective solutions for connecting them are crucial to maximize efficiency and open up new digital solution possibilities. However, the ability to remotely manage tens of millions of ESL across hundreds of stores through one cloud-based network had not yet been possible until Hanshow partnered with Microsoft to develop a SaaS solution that can handle this massive amount of integration.
Adopting solutions through cloud services and IoT technology is rapidly growing in retail. Global research firm Gartner estimates, “Worldwide end-user spending on public cloud services is forecast to grow 18.4% in 2021 to total $304.9 billion, up from $257.5 billion in 2020”.* It further adds, “Although software as a service (SaaS) remains the largest market segment and is forecast to grow to $117.7 billion in 2021, application infrastructure services (PaaS) is anticipated to grow by a higher margin at 26.6%” *
The benefits of adopting such services are apparent through this partnership. The Hanshow SaaS solution addresses a number of challenges for retailers such as staffing surges during peak times, labor costs, space constraints, and overall productivity.
Under previous scenarios, retailers have to install and operate their own system of servers and infrastructure on premise requiring a massive investment, untold time to set up, and significant input from IT professionals.
The Hanshow SaaS Solution provides global retailers an intelligent, easy-to-deploy, user-friendly, and analytics driven platform. Hanshow SaaS is ready on arrival and can be accessed instantly anytime, anywhere. Data can be shared across geographies while remote monitoring and updates become a seamless exercise. Price updates and other ESL or digital solution updates can be done at breakneck pace; 3 million ESL can be updated in just 80 min. And with a focus on the heightened security needed from a cloud-based network, Hanshow carried out third-party security testing through a leading global security firm to certify data safety of the Microsoft Azure backed Hanshow SaaS.
“This scale and advancement in retail technology was made possible through the safety, stability, scalability and speed of Microsoft SaaS with Hanshow’s innovative management software,” said Raj Raguneethan, regional leader, Retail & Consumer Goods at Microsoft Asia. “With this work, we’re seeing only the beginning of what’s possible with IoT and SaaS.”
While over 10 million ESL have already integrated into the Hanshow SaaS, it can handle much more if necessary. “By integrating retail digitization with SaaS, the possibilities are endless,” said Hanshow Executive Chairman and CEO Shiguo Hou. “This is the future. We're committed to bringing these benefits to customers and retailers on an even grander scale.”
*Gartner Press Release, “Gartner Forecasts Worldwide Public Cloud End-User Spending to Grow 18% in 2021”, 17 November 2020, [https://www.gartner.com/en/newsroom/press-releases/2020-11-17-gartner-forecasts-worldwide-public-cloud-end-user-spending-to-grow-18-percent-in-2021 ]
About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. As an innovation leader in the industry, Hanshow is dedicated to offering its global customers a series of world-class customized IoT touchpoints and digital store solutions. Hanshow’s intelligence-enabled platforms and systems deliver customer-centric insights, helping retailers streamline operations and providing various solutions to support optimal pricing strategies to offer consumers a more personalized experience. Hanshow currently serves over 20,000 stores in more than 50 countries. For more information, please visit www.hanshow.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210607005244/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom